Trial of Belimumab in Early Lupus

This two year study will evaluate the effects of giving belimumab (Benlysta) to patients with Early Lupus. Early lupus is a diagnosis of lupus within 2 years. Subjects will be randomized to receive belimumab or placebo during the first year. During the second year, subjects who were randomized to belimumab will be rerandomized to continue to receive belimumab or to receive placebo. The study will look at clinical effects as well as effects on the immune system.

NCT Number	NCT03543839
Lead Sponsor	Northwell Health Collaborators: GlaxoSmithKline
Conditions	Lupus Erythematosus, Systemic, Lupus Erythematosus
Enrollment	30 participants
Start Date	2020-09-15
Primary Completion	2028-09 (estimated)
Study Completion	2029-03 (estimated)
Updated on ClinicalTrials.gov	2026-06-12